NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

中國的Golimumab市場的相關調查報告書(2021年∼2025年)

Investigation Report on China's Golimumab Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1008258
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Golimumab市場的相關調查報告書(2021年∼2025年) Investigation Report on China's Golimumab Market 2021-2025
出版日期: 2021年05月28日內容資訊: 英文 50 Pages
簡介

在中國市場的Golimumab的銷售量從2018年到2020年有急速增加趨勢。2020年的年度銷售量為632萬人民幣,增加到2018年的10倍以上。從2018年到2020年的中國市場中Golimumab的銷售量以242.6%的年複合成長率的成長。急速成長主要理由,Golimumab包含在2019年中國的醫療保險,在風濕的領域進入全國醫療保險類別B的清單。

本報告提供中國的Golimumab市場的相關調查,市場規模和預測,趨勢,COVID-19的影響,價格,成長要素和課題,威脅,課題,市場佔有率等資訊。

目錄

第1章 Golimumab的相關概念

  • Golimumab的適應症
  • 中國的Golimumab的開發
  • 中國的Golimumab的政府核准
  • COVID-19對中國的Golimumab銷售的影響

第2章 中國的Golimumab銷售(2018-2020)

  • Golimumab的銷售額
    • 總銷售額
    • 各地區的銷售量
  • Golimumab的銷售量
    • 整體銷售量
    • 各地區銷售量
  • 中國的各劑型Golimumab銷售(2018-2020)
    • 注射
    • 其他的劑型分析

第3章 中國的主要Golimumabmeka分析(2018-2020)

  • 主要的Golimumabmeka的市場佔有率分析
    • 各銷售額市場佔有率調查
    • 各銷售量市場佔有率調查
  • Janssen Biologics BV
    • 企業簡介
    • SIMPONI(Janssen Biologics BV的Golimumab)的中國的銷售

第4章 中國的各種製造商Golimumab的價格(2020-2021)

  • Janssen Biologics BV(SIMPONI)

第5章 中國的Golimumab市場預測(2021-2025)

  • 中國的Golimumab市場開發的有影響力的要素
    • COVID-19對中國的Golimumab市場的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2105493

Golimumab is an immunosuppressive medication that can effectively regulate inflammation and bone metabolism. The trade name of Golimumab is SIMPONI, which was developed by Janssen Biologics BV. Its products were launched in China for the treatment of ankylosing spondylitis(AS)and rheumatoid arthritis (RA) in 2018. As of the first half of 2021, Janssen Biologics BV is the only manufacturer in the Chinese Golimumab market.

According to CRI's market research, the sales of Golimumab in the Chinese market have had a rapid upward trend from 2018 to 2020. The annual sales revenue in 2020 is CNY6.32 million, which increased over 10 times compared to that in 2018. The CAGR of Golimumab sales in the Chinese market in 2018-2020 is 242.6%. The main reason for the rapid growth is that Golimumab was included in China's medical insurance in 2019 and it entered the national medical insurance category B list in the field of rheumatism.

CRI analyzes that from 2021 to 2025,the sales will continue to increase due to its superior efficacy and low injection frequency. In addition, Golimumab will have a very broad market and the penetration rate of SIMPONI can be improved in the future. Therefore, the market share of Golimumab has the potential to increase, which will lead the sales volume to grow in the future.

Topics Covered:

  • The impact of COVID-19 on China's Golimumab market
  • Sales value of China's Golimumab 2016-2020
  • Competitive landscape of China's Golimumab market
  • Prices of Golimumab in China
  • Prices of Golimumab in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Golimumab market
  • Prospect of China's Golimumab market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Golimumab

  • 1.1 Indications for Golimumab
  • 1.2 Development of Golimumab in China
  • 1.3 Governmental Approval of Golimumab in China
  • 1.4 The Impact of COVID-19 on Golimumab sales in China

2 Sales of Golimumab in China, 2018-2020

  • 2.1 Sales Value of Golimumab
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Regions
  • 2.2 Sales Volume of Golimumab
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Regions
  • 2.3 Sales of Golimumab by Dosage Form in China, 2018-2020
    • 2.3.1 Injection
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Golimumab Manufacturers in China, 2018-2020

  • 3.1 Analysis of Market Share of Major Golimumab Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Janssen Biologics BV
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of SIMPONI (Janssen Biologics BV's Golimumab) in China

4 Prices of Golimumab for Different Manufacturers in China, 2020-2021

  • 4.1 Janssen Biologics BV (SIMPONI)

5 Prospect of Chinese Golimumab Market, 2021-2025

  • 5.1 Influential Factors of Chinese Golimumab Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Golimumab Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Golimumab Injection Registration in China
  • Chart Sales Value of Golimumab Injection over the World
  • Chart Sales Value of Golimumab Injection in China, 2018-2020
  • Chart Sales Value of Golimumab Injection in China by Regions, 2018-2020
  • Chart Sales Volume of Golimumab Injection in China, 2018-2020
  • Chart Sales Volume of Golimumab Injection in China by Regions, 2018-2020
  • Chart Market Share by Sales Value of Top Golimumab Manufacturers in China, 2018-2020
  • Chart Sales Value and Volume of SIMPONI in China, 2018-2020
  • Chart Referential Prices of SIMPONI in China by regions, 2020-2021
  • Chart Forecast on Sales Value of Golimumab in China, 2021-2025
  • Chart Forecast on Sales Volume of Golimumab in China, 2021-2025